OB-X Trademark

Trademark Overview

On Wednesday, September 30, 2009, a trademark application was filed for OB-X with the United States Patent and Trademark Office. The USPTO has given the OB-X trademark a serial number of 77838545. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 24, 2023. This trademark is owned by ANGIOLAB., INC.. The OB-X trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of angiogenesis-dependent diseases, namely, obesity, cancer, arthritis, psoriasis, and ocular diseases, and diagnostic preparations for veterinary use for the treatment of angiogenesis-dependent diseases; dietary supplements and dietetic foods adapted for medical use for the treatment of angiogenesis-dependent diseases, namely, obesity, cancer, arthritis, psoriasis, and ocular diseases
ob-x

General Information

Serial Number77838545
Word MarkOB-X
Filing DateWednesday, September 30, 2009
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 24, 2023
Registration Number4206301
Registration DateTuesday, September 11, 2012
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 1, 2010

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of angiogenesis-dependent diseases, namely, obesity, cancer, arthritis, psoriasis, and ocular diseases, and diagnostic preparations for veterinary use for the treatment of angiogenesis-dependent diseases; dietary supplements and dietetic foods adapted for medical use for the treatment of angiogenesis-dependent diseases, namely, obesity, cancer, arthritis, psoriasis, and ocular diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 24, 2023
Primary Code005
First Use Anywhere DateWednesday, April 5, 2006
First Use In Commerce DateThursday, December 31, 2009

Trademark Owner History

Party NameANGIOLAB., INC.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressDaejeon 305340
KR
Party NameANGIOLAB., INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressDaejeon 305340
KR
Party NameANGIOLAB., INC.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressDaejeon 305340
KR

Trademark Events

Event DateEvent Description
Friday, March 24, 2023CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9
Friday, February 11, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, February 11, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, February 11, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Saturday, September 11, 2021COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Wednesday, September 5, 2018NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Wednesday, September 5, 2018REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Wednesday, September 5, 2018CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, August 27, 2018TEAS SECTION 8 & 15 RECEIVED
Monday, September 11, 2017COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, September 11, 2012REGISTERED-PRINCIPAL REGISTER
Friday, August 10, 2012NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Thursday, August 9, 2012LAW OFFICE REGISTRATION REVIEW COMPLETED
Thursday, August 2, 2012ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, August 2, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, August 2, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 26, 2012TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, February 1, 2012NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, February 1, 2012FINAL REFUSAL E-MAILED
Wednesday, February 1, 2012SU - FINAL REFUSAL - WRITTEN
Wednesday, February 1, 2012TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 1, 2012CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 25, 2012TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 26, 2011NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 26, 2011NON-FINAL ACTION E-MAILED
Tuesday, July 26, 2011SU - NON-FINAL ACTION - WRITTEN
Tuesday, July 26, 2011STATEMENT OF USE PROCESSING COMPLETE
Friday, July 15, 2011USE AMENDMENT FILED
Tuesday, July 26, 2011CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, July 15, 2011TEAS STATEMENT OF USE RECEIVED
Saturday, January 29, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 27, 2011SOU EXTENSION 1 GRANTED
Thursday, January 27, 2011SOU EXTENSION 1 FILED
Thursday, January 27, 2011TEAS EXTENSION RECEIVED
Tuesday, July 27, 2010NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 1, 2010OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 1, 2010PUBLISHED FOR OPPOSITION
Monday, April 26, 2010LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, April 26, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 26, 2010PREVIOUS ALLOWANCE COUNT WITHDRAWN
Monday, April 26, 2010APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 26, 2010EXAMINER'S AMENDMENT ENTERED
Monday, April 26, 2010NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Monday, April 26, 2010EXAMINERS AMENDMENT E-MAILED
Monday, April 26, 2010EXAMINERS AMENDMENT -WRITTEN
Thursday, April 15, 2010TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 15, 2010CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, April 15, 2010ASSIGNED TO LIE
Monday, April 5, 2010TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, January 1, 2010NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 1, 2010NON-FINAL ACTION E-MAILED
Friday, January 1, 2010NON-FINAL ACTION WRITTEN
Monday, December 28, 2009ASSIGNED TO EXAMINER
Friday, October 9, 2009NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, October 3, 2009NEW APPLICATION ENTERED

Related Keywords

diseases dependent angiogenesis treatment psoriasis ocular cancer arthritis obesity namely